AtaiBeckley Inc (NASDAQ:ATAI) is among the best psychedelic stocks to buy in 2026. On March 17, AtaiBeckley Inc (NASDAQ:ATAI) ...

Atai Life Sciences (ATAI) this past Friday, July 25, 2025 reported results from its phase 2b study using its drug inidascamine for the treatment of patients with cognitive impairment associated with ...

How over-the-top social media videos about psychedelics could undermine the field’s efforts to get its drugs approved.

AtaiBeckley (NasdaqGM:ATAI) reported positive, peer reviewed Phase 2a results for its lead psychedelic drug BPL-003 in ...

NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

AtaiBeckley is a clinical-stage psychedelic biotech targeting TRD and SAD, with BPL-003 as its lead value driver. BPL-003 posted encouraging depression data and has the FDA’s Breakthrough Therapy ...

atai Life Sciences and Beckley Psytech’s psychedelic medicine will progress to Phase III following its mid-stage success in treatment-resistant depression (TRD). This follows the positive results of ...

Privately held Beckley Psytech Ltd. is to be taken over by Atai Life Sciences in an all-share deal that values the U.K. psychedelic drug specialist at $370 million. After making a $50 million ...

Atai Life Sciences (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy according to analysts. On July 29, Oppenheimer initiated coverage of the stock with an ‘Outperform’ rating and a $14 ...

Depression remains one of the world’s most debilitating conditions, impacting millions worldwide with symptoms that can disrupt every facet of life — from work and relationships to basic daily ...

Atai Life Sciences N.V. (NASDAQ:ATAI) is one of the best healthcare penny stocks to buy now. On September 15, H.C. Wainwright reiterated a ‘Buy’ rating on the stock and a $15 price target. The ...